Virtus ETF Advisers’s MyoKardia, Inc. Common Stock MYOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-3,282
| Closed | -$447K | – | 367 |
|
|
2020
Q3 | $447K | Sell |
3,282
-439
| -12% | -$46.7K | 0.23% | 148 |
|
|
2020
Q2 | $360K | Sell |
3,721
-1,662
| -31% | -$139K | 0.17% | 253 |
|
|
2020
Q1 | $252K | Sell |
5,383
-791
| -13% | -$50.7K | 0.1% | 249 |
|
|
2019
Q4 | $450K | Buy |
6,174
+687
| +13% | +$41.7K | 0.07% | 220 |
|
|
2019
Q3 | $286K | Sell |
5,487
-304
| -5% | -$16.2K | 0.06% | 202 |
|
|
2019
Q2 | $290K | Buy |
5,791
+932
| +19% | +$45.4K | 0.06% | 231 |
|
|
2019
Q1 | $253K | Sell |
4,859
-735
| -13% | -$33.9K | 0.54% | 78 |
|
|
2018
Q4 | $273K | Sell |
5,594
-4,072
| -42% | -$224K | 0.05% | 142 |
|
|
2018
Q3 | $630K | Sell |
9,666
-6,914
| -42% | -$407K | 0.07% | 94 |
|
|
2018
Q2 | $823K | Sell |
16,580
-3,022
| -15% | -$146K | 0.73% | 20 |
|
|
2018
Q1 | $957K | Buy |
19,602
+10,155
| +107% | +$528K | 0.83% | 47 |
|
|
2017
Q4 | $398K | Sell |
9,447
-1,715
| -15% | -$66.1K | 0.5% | 54 |
|
|
2017
Q3 | $478K | Sell |
11,162
-10,245
| -48% | -$327K | 0.06% | 94 |
|
|
2017
Q2 | $280K | Buy |
21,407
+521
| +2% | +$6.87K | 0.04% | 136 |
|
|
2017
Q1 | $275K | Buy |
20,886
+2,002
| +11% | +$25.6K | 0.05% | 148 |
|
|
2016
Q4 | $245K | Buy |
+18,884
| New | +$291K | 0.07% | 149 |
|
Virtus ETF Advisers's MYOK Position: Q4 2020 in Review
Virtus ETF Advisers sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 3,282 shares — an estimated $447K sold.
Virtus ETF Advisers first reported a position in MYOK in Q4 2016 and held it in 16 quarters. The position peaked at $957K in Q1 2018. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.
- Virtus ETF Advisers reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
- Virtus ETF Advisers sold 3,282 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $447K.
- Virtus ETF Advisers first reported a position in MyoKardia, Inc. Common Stock in Q4 2016 and held it in 16 quarters.
- Virtus ETF Advisers's MyoKardia, Inc. Common Stock position peaked at $957K in Q1 2018.
- 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.
Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.